Table 3 Recurrence and progression after PUNLMP reported in the literature and in this study
Study | No. | Recur (any) (%) | Recur PUNLMP (%) | Progress (LG, HG, CIS) (%) | Progress to LG (%) | Progress to HG (%) | Progress with invasion (%) | Mortality (%) |
|---|---|---|---|---|---|---|---|---|
[5] | 112 | 29.5 | 3.6 | 10.7 | 3.6 | 3.6 | 3.6 | 2.7 |
[6] | 8 | 33.3 | NA | 0 | NA | NA | 0 | 0 |
[21] | 20 | 25 | 25 | 0 | 0 | 0 | 0 | NA |
[7] | 68 | 32.4 | NA | 0 | NA | NA | NA | 0 |
[8] | 116 | 32.8 | NA | 2.6 | NA | NA | NA | 0.9 |
[9] | 19 | 47.4 | NA | NA | NA | NA | NA | NA |
[22] | 29 | NA | NA | 6.9 | NA | NA | 6.9 | NA |
[10] | 53 | 60 | 30 | 42 | 34 | 0 | 8 | 0 |
[11] | 45 | 62.2 | NA | NA | NA | NA | NA | NA |
[14] | 12 | 25 | NA | 8.3 | 8.3 | 0 | 0 | NA |
[18] | 27 | 51.9 | 51.9 | 0 | 0 | 0 | 0 | 0.0 |
[12] | 85 | 47.1 | 47.1 | 0 | 0 | 0 | 0 | NA |
[13] | 212 | 17.9 | NA | 1.9 | NA | NA | NA | 0 |
[15] | 31 | 41.9 | 12.9 | 29.0 | 25.8 | 3.2 | 0 | 0 |
Current study | 189 | 20.1 | 9 | 11.1 | 9.5 | 1.6 | 1.0 | 0 |
Range | 8-212 | 16.7-62.2 | 3.6-51.9 | 0-42 | 0-34 | 0-3.6 | 0-8 | 0-2.7 |